• 1
    Lotze MT,Herberman RB. Cancer as a chronic inflammatory disease: role of immunotherapy in cancer and inflammation. In: MorganDW,NakadaM,ForssmannUJ. Cancer and inflammationed. Boston: Birkhauser Verlag 2004. 2151.
  • 2
    Bouma G,Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 52133.
  • 3
    Wirtz S,Neurath MF. Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int J Colorectal Dis 2000; 15: 14460.
  • 4
    Itzkowitz SH,Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G7G17.
  • 5
    Delgado M,Pozo D,Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56: 24990.
  • 6
    Vaudry D,Gonzalez BJ,Basille M,Yon L,Fournier A,Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2000; 52: 269324.
  • 7
    Delgado M,Abad C,Martinez C,Leceta J,Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 5638.
  • 8
    Abad C,Martinez C,Leceta J,Gomariz RP,Delgado M. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol 2001; 167: 31829.
  • 9
    Abad C,Martinez C,Juarranz MG,Arranz A,Leceta J,Delgado M,Gomariz RP. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003; 124: 96171.
  • 10
    Kato H,Ito A,Kawanokuchi J,Jin S,Mizuno T,Ojika K,Ueda R,Suzumura A. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult Scler 2004; 10: 6519.
  • 11
    Gonzalez-Rey E,Fernandez-Martin A,Chorny A,Martin J,Pozo D,Ganea D,Delgado M. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 2006; 168: 117988.
  • 12
    Institute of Laboratory Animal Resources CoLS, National Research Council. Guide for the Care and Use of Laboratory Animalsed. Washington, DC: National Academy Press, 1996.
  • 13
    Cooper HS,Murthy SN,Shah RS,Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 23849.
  • 14
    Gray SL,Yamaguchi N,Vencova P,Sherwood NM. Temperature-sensitive phenotype in mice lacking pituitary adenylate cyclase-activating polypeptide. Endocrinology 2002; 143: 394654.
  • 15
    Sturlan S,Oberhuber G,Beinhauer BG,Tichy B,Kappel S,Wang J,Rogy MA. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 2001; 22: 66571.
  • 16
    Rudolph U,Finegold MJ,Rich SS,Harriman GR,Srinivasan Y,Brabet P,Boulay G,Bradley A,Birnbaumer L. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet 1995; 10: 14350.
  • 17
    Huang EH,Park JC,Appelman H,Weinberg AD,Banerjee M,Logsdon CD,Schmidt AM. Induction of inflammatory bowel disease accelerates adenoma formation in Min +/− mice. Surgery 2006; 139: 7828.
  • 18
    Schlemper RJ,Riddell RH,Kato Y,Borchard F,Cooper HS,Dawsey SM,Dixon MF,Fenoglio-Preiser CM,Flejou JF,Geboes K,Hattori T,Hirota T, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 2515.
  • 19
    Riddell RH. Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Am J Gastroenterol 1996; 91: 86472.
  • 20
    Boivin GP,Washington K,Yang K,Ward JM,Pretlow TP,Russell R,Besselsen DG,Godfrey VL,Doetschman T,Dove WF,Pitot HC,Halberg RB, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003; 124: 76277.
  • 21
    Cooper HS,Murthy S,Kido K,Yoshitake H,Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000; 21: 75768.
  • 22
    Okayasu I,Yamada M,Mikami T,Yoshida T,Kanno J,Ohkusa T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 2002; 17: 107883.
  • 23
    Greten FR,Eckmann L,Greten TF,Park JM,Li ZW,Egan LJ,Kagnoff MF,Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 28596.
  • 24
    Kohno H,Suzuki R,Sugie S,Tanaka T. Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci 2005; 96: 6976.
  • 25
    Suzuki R,Kohno H,Sugie S,Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci 2004; 95: 7217.
  • 26
    Tanaka T,Kohno H,Suzuki R,Yamada Y,Sugie S,Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 96573.
  • 27
    Wang JG,Wang DF,Lv BJ,Si JM. A novel mouse model for colitis-associated colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sulfate sodium. World J Gastroenterol 2004; 10: 295862.
  • 28
    Takahashi M,Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 2004; 95: 47580.
  • 29
    Rennick DM,Fort MM,Davidson NJ. Studies with IL-10-/- mice: an overview. J Leukoc Biol 1997; 61: 38996.
  • 30
    Wu JY,Jin Y,Edwards RA,Zhang Y,Finegold MJ,Wu MX. Impaired TGF-beta responses in peripheral T cells of G alpha i2-/- mice. J Immunol 2005; 174: 61228.
  • 31
    Fujii S,Fujimori T,Kawamata H,Takeda J,Kitajima K,Omotehara F,Kaihara T,Kusaka T,Ichikawa K,Ohkura Y,Ono Y,Imura J, et al. Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut 2004; 53: 7106.
  • 32
    Delgado M,Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 2001; 167: 96675.
  • 33
    Delgado M,Gomariz RP,Martinez C,Abad C,Leceta J. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 2000; 30: 323646.
  • 34
    Delgado M,Reduta A,Sharma V,Ganea D. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. J Leukoc Biol 2004; 75: 112230.
  • 35
    Delgado M,Gonzalez-Rey E,Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 2005; 175: 731124.
  • 36
    Chorny A,Gonzalez-Rey E,Fernandez-Martin A,Pozo D,Ganea D,Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 2005; 102: 135627.
  • 37
    Fernandez-Martin A,Gonzalez-Rey E,Chorny A,Ganea D,Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 2006; 36: 31826.
  • 38
    Waschek JA. Multiple actions of pituitary adenylyl cyclase activating peptide in nervous system development and regeneration. Dev Neurosci 2002; 24: 1423.
  • 39
    Ogasawara M,Murata J,Kamitani Y,Hayashi K,Saiki I. Inhibition by vasoactive intestinal polypeptide (VIP) of angiogenesis induced by murine Colon 26-L5 carcinoma cells metastasized in liver. Clin Exp Metastasis 1999; 17: 28391.
  • 40
    Toumi F,Neunlist M,Cassagnau E,Parois S,Laboisse CL,Galmiche JP,Jarry A. Human submucosal neurones regulate intestinal epithelial cell proliferation: evidence from a novel coculture model. Neurogastroenterol Motil 2003; 15: 23942.
  • 41
    Lelievre V,Meunier AC,Caigneaux E,Falcon J,Muller JM. Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. Cell Signal 1998; 10: 1326.